[HTML][HTML] Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer
T Mok, Y Wu, JS Au, C Zhou, L Zhang, RP Perng… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …
significantly increases survival for patients with previously treated advanced non-small cell …
[PDF][PDF] Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
T Mok, Y Wu, JS Au, C Zhou, L Zhang… - Journal of Thoracic …, 2010 - scholar.archive.org
Results: Best response data were available for 1118 E/SE Asian and 4276 non-E/SE Asian
patients. The overall response rates were 27% versus 10%, respectively (p 0.0001). The …
patients. The overall response rates were 27% versus 10%, respectively (p 0.0001). The …
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer
T Mok, Y Wu, JS Au, C Zhou… - Journal of thoracic …, 2010 - pubmed.ncbi.nlm.nih.gov
Introduction Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …
significantly increases survival for patients with previously treated advanced non-small cell …
[PDF][PDF] Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
T Mok, Y Wu, JS Au, C Zhou, L Zhang… - Journal of Thoracic …, 2010 - core.ac.uk
Results: Best response data were available for 1118 E/SE Asian and 4276 non-E/SE Asian
patients. The overall response rates were 27% versus 10%, respectively (p 0.0001). The …
patients. The overall response rates were 27% versus 10%, respectively (p 0.0001). The …
Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
T Mok, YL Wu, JSK Au, CC Zhou… - JOURNAL OF …, 2010 - scholarworks.bwise.kr
Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …
significantly increases survival for patients with previously treated advanced non-small cell …
Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
T Mok, Y Wu, JS Au, C Zhou, L Zhang, RP Perng… - Journal of Thoracic …, 2010 - jto.org
Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …
significantly increases survival for patients with previously treated advanced non-small cell …
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
T Mok, YL Wu, JS Au, C Zhou, L Zhang… - Journal of Thoracic …, 2010 - europepmc.org
Methods Patients who had previously failed on chemotherapy or radiotherapy, or were
unsuitable for these treatments, were treated with oral erlotinib (150 mg/d) until disease …
unsuitable for these treatments, were treated with oral erlotinib (150 mg/d) until disease …